Skip to main content

Table 3 Summary of glucocorticoid use at index and during 6 months post-index

From: Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation

 

FAS (N = 53)

Index

Post-index

Glucocorticoid use, n (%)

50 (94.3)

50 (94.3)

Discontinued

1 (2.0)

Glucocorticoid dose, mg/day, mean (SD)

12.2 (7.3)

8.6 (5.1)

Change from index to 6 months post-indexa

 

–3.6 (5.2)

Glucocorticoid dose category, n (%)

≥7.5 mg/day

38 (77.6)a

30 (62.50)b

<7.5 mg/day

11 (22.4)a

18 (37.5)b

Change in dose category from index to 6 months post-index, n (%)a

Remained on <7.5 mg/day

10 (20.4)

Shifted from <7.5 mg/day to ≥7.5 mg/day

1 (2.0)

Shifted from ≥7.5 mg/day to discontinued

1 (2.0)

Remained on ≥7.5 mg/day

29 (59.2)

Shifted from ≥7.5 mg/day to <7.5 mg/day

8 (16.3)

  1. FAS full analysis set, SD standard deviation
  2. aData for 49 patients with glucocorticoid dose data at both time points
  3. bData for 48 patients, excluding one patient who discontinued